Results of correction of the hepatic steatosis on the background of hypertension and overweight with help of essential phospholipid complex

dc.contributor.authorBabak, Oleg
dc.contributor.authorBashkirova, Anna
dc.date.accessioned2019-05-21T13:19:28Z
dc.date.available2019-05-21T13:19:28Z
dc.date.issued2019-03
dc.description.abstractOne of the unfavorable factors contributing to the forma- tion of cardiovascular risk in non-alcoholic fatty liver disease (NAFLD) on the background of hypertension is the low level of HDL cholesterol, in the metabolism of which the activity of endothelial lipase (EL) plays a leading role. The liver plays an important role in the formation of dyslipidemia and is a target for lipid metabolism disorders, representing one of the pathoge- netic stages of NAFLD formation, which dictates the search for ways of drug “support” of hepatocytes. The aim of the research was to study the effectiveness of es- sential phospholipids in the complex therapy of patients with NAFLD, hypertension and overweight, taking into account the ynamics of laboratory and instrumental examinations and EL blood level. 52 patients with NAFLD on the background of hypertension and overweight have been examined. The control group con- sisted of 20 practically healthy people. All patients were divided with accordance of age and sex. Dietary nutrition with reduction of simple carbohydrates and fats was recommended for patients and treatment with essential phospholipids for 6 months at a dose of 2 capsules 3 times a day was prescribed. 16 patients of the main group showed complete compliance till the end of the course of treatment. The concen- tration of EL was determined by the ELISA using the Aviscera Bioscience INC reagents kit (USA). The complex of essential phospholipids as additional com- ponent for diet showed an effective decrease in the severity of hepatic steatosis in combination with the reduction of insulin re- sistance, as well as the restoration of normal pathogenetic func- tional links between HDL and endothelial lipase in patients with NAFLD on background of hypertension. Thus essential phospholipids can be recommended to reduce CVD and comorbidity for all patient`s with these diseases, which was mentioned above, despite the range of steatosis.ru_RU
dc.identifier.citationBabak O. Results of correction of the hepatic steatosis on the background of hypertension and overweight with help of essential phospholipid complex / O. Babak, A. Bashkirova // Georgian medical news. – 2019. – N 3 (288). – P. 86–91.ru_RU
dc.identifier.urihttps://repo.knmu.edu.ua/handle/123456789/22969
dc.language.isoenru_RU
dc.subjectnon-alcoholic fatty liver diseaseru_RU
dc.subjecthypertensionru_RU
dc.subjectendothelial lipaseru_RU
dc.subjectessential phospholipidsru_RU
dc.titleResults of correction of the hepatic steatosis on the background of hypertension and overweight with help of essential phospholipid complexru_RU
dc.typeArticleru_RU

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
86-91-2.pdf
Size:
1.12 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
11.51 KB
Format:
Item-specific license agreed upon to submission
Description: